• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

耐碳青霉烯类不动杆菌感染的流行病学、治疗及转归的最新进展

Update on the Epidemiology, Treatment, and Outcomes of Carbapenem-resistant Acinetobacter infections.

作者信息

Kim Uh Jin, Kim Hee Kyung, An Joon Hwan, Cho Soo Kyung, Park Kyung-Hwa, Jang Hee-Chang

机构信息

Department of Infectious Diseases, Chonnam National University Medical School, Gwangju, Korea.

出版信息

Chonnam Med J. 2014 Aug;50(2):37-44. doi: 10.4068/cmj.2014.50.2.37. Epub 2014 Aug 20.

DOI:10.4068/cmj.2014.50.2.37
PMID:25229014
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4161759/
Abstract

Carbapenem-resistant Acinetobacter species are increasingly recognized as major nosocomial pathogens, especially in patients with critical illnesses or in intensive care. The ability of these organisms to accumulate diverse mechanisms of resistance limits the available therapeutic agents, makes the infection difficult to treat, and is associated with a greater risk of death. In this review, we provide an update on the epidemiology, resistance mechanisms, infection control measures, treatment, and outcomes of carbapenem-resistant Acinetobacter infections.

摘要

耐碳青霉烯类不动杆菌属日益被认为是主要的医院病原体，尤其是在危重病患者或重症监护患者中。这些微生物积累多种耐药机制的能力限制了可用的治疗药物，使感染难以治疗，并与更高的死亡风险相关。在本综述中，我们提供了关于耐碳青霉烯类不动杆菌感染的流行病学、耐药机制、感染控制措施、治疗及结果的最新信息。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f76/4161759/42d1d776274b/cmj-50-37-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f76/4161759/f421f2ed540c/cmj-50-37-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f76/4161759/42d1d776274b/cmj-50-37-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f76/4161759/f421f2ed540c/cmj-50-37-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f76/4161759/42d1d776274b/cmj-50-37-g002.jpg

相似文献

1
Update on the Epidemiology, Treatment, and Outcomes of Carbapenem-resistant Acinetobacter infections.耐碳青霉烯类不动杆菌感染的流行病学、治疗及转归的最新进展
Chonnam Med J. 2014 Aug;50(2):37-44. doi: 10.4068/cmj.2014.50.2.37. Epub 2014 Aug 20.
2
Phenotypic and molecular characterization of Acinetobacter baumannii isolates causing lower respiratory infections among ICU patients.分析 ICU 患者下呼吸道感染的鲍曼不动杆菌分离株的表型和分子特征。
Microb Pathog. 2019 Mar;128:75-81. doi: 10.1016/j.micpath.2018.12.023. Epub 2018 Dec 15.
3
Epidemiological, Physiological, and Molecular Characteristics of a Brazilian Collection of Carbapenem-Resistant Acinetobacter baumannii and Pseudomonas aeruginosa.巴西耐碳青霉烯类鲍曼不动杆菌和铜绿假单胞菌菌株收集物的流行病学、生理学及分子特征
Microb Drug Resist. 2017 Oct;23(7):852-863. doi: 10.1089/mdr.2016.0219. Epub 2017 Feb 24.
4
Spread of a carbapenem- and colistin-resistant Acinetobacter baumannii ST2 clonal strain causing outbreaks in two Sicilian hospitals.碳青霉烯类和多黏菌素耐药鲍曼不动杆菌 ST2 克隆株的传播导致西西里岛两家医院暴发疫情。
J Hosp Infect. 2014 Apr;86(4):260-6. doi: 10.1016/j.jhin.2014.02.001. Epub 2014 Feb 20.
5
Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance.耐黏菌素鲍曼不动杆菌：超越碳青霉烯类耐药性
Clin Infect Dis. 2015 May 1;60(9):1295-303. doi: 10.1093/cid/civ048. Epub 2015 Jan 28.
6
In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii.黏菌素与替加环素或β-内酰胺类抗生素/β-内酰胺酶抑制剂组合对耐碳青霉烯类鲍曼不动杆菌的体外协同活性。
J Int Med Res. 2013 Dec;41(6):1830-7. doi: 10.1177/0300060513496172.
7
[Evaluation of the efficacy of colistin/sulbactam combination on carbapenem-resistant Acinetobacter baumannii strains].[多黏菌素/舒巴坦联合用药对耐碳青霉烯类鲍曼不动杆菌菌株的疗效评估]
Mikrobiyol Bul. 2016 Jul;50(3):460-5. doi: 10.5578/mb.26289.
8
Carbapenem resistance in Pseudomonas aeruginosa and Acinetobacter baumannii in the nosocomial setting in Latin America.拉丁美洲医院环境中铜绿假单胞菌和鲍曼不动杆菌对碳青霉烯类抗生素的耐药性
Crit Rev Microbiol. 2016;42(2):276-92. doi: 10.3109/1040841X.2014.940494. Epub 2014 Aug 27.
9
Emergence of colistin and carbapenem-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii (CCR-Acb) complex in a neurological intensive care unit followed by successful control of the outbreak.神经营养重症监护病房中出现对黏菌素和碳青霉烯类药物耐药的鲍氏不动杆菌-醋酸钙不动杆菌复合群（CCR-Acb），随后成功控制了疫情。
J Infect Public Health. 2020 Apr;13(4):564-570. doi: 10.1016/j.jiph.2019.09.013. Epub 2019 Oct 29.
10
Growing OXA-23 type strains among carbapenem-resistant and tigecycline as an alternate combination therapy.耐碳青霉烯类抗生素和替加环素的 OXA-23 型菌株不断增加，后者可作为替代联合治疗方案。
Turk J Med Sci. 2016 Dec 20;46(6):1894-1899. doi: 10.3906/sag-1508-20.

引用本文的文献

1
Phenotypic and Genotypic Characterization of Clinical Isolates of Carbapenem-Resistant Acinetobacter baumannii: A Cross-Sectional Study From a Tertiary Care Hospital in Western Uttar Pradesh, India.耐碳青霉烯鲍曼不动杆菌临床分离株的表型和基因型特征：来自印度北方邦西部一家三级护理医院的横断面研究
Cureus. 2025 May 12;17(5):e83998. doi: 10.7759/cureus.83998. eCollection 2025 May.
2
Exploring fluoroquinolone resistance mechanisms and the effects of carbonyl cyanide 3-chlorophenylhydrazone (CCCP) in .探索氟喹诺酮耐药机制以及羰基氰3-氯苯腙（CCCP）在……中的作用
Front Med (Lausanne). 2025 May 9;12. doi: 10.3389/fmed.2025.1527662. eCollection 2025.
3

本文引用的文献

1
Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections.黏菌素与黏菌素联合磷霉素治疗耐碳青霉烯类鲍曼不动杆菌感染的初步研究
Antimicrob Agents Chemother. 2014 Sep;58(9):5598-601. doi: 10.1128/AAC.02435-13. Epub 2014 Jun 30.
2
Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort.多药耐药鲍曼不动杆菌所致脓毒症的单药治疗与联合治疗：一项多中心前瞻性队列分析
J Antimicrob Chemother. 2014 Nov;69(11):3119-26. doi: 10.1093/jac/dku233. Epub 2014 Jun 25.
3
Fluopsin C Promotes Biofilm Removal of XDR and Presents an Additive Effect with Polymyxin B on Planktonic Cells.
荧光素C促进多重耐药菌生物膜的清除，并与多粘菌素B对浮游细胞呈现相加作用。
Antibiotics (Basel). 2024 Sep 12;13(9):875. doi: 10.3390/antibiotics13090875.
4
Promising New Targets for the Treatment of Infections Caused by : A Review.治疗由......引起的感染的有前途的新靶点：综述。
Curr Drug Targets. 2024;25(14):971-986. doi: 10.2174/0113894501319269240819060245.
5
Epidemiology and antimicrobial resistance trends of species in the United Arab Emirates: a retrospective analysis of 12 years of national AMR surveillance data.阿联酋种的流行病学和抗菌药物耐药趋势：对 12 年国家抗菌药物耐药监测数据的回顾性分析。
Front Public Health. 2024 Jan 4;11:1245131. doi: 10.3389/fpubh.2023.1245131. eCollection 2023.
6
Structural diversity among K-antigens and its implication in the serotyping.K抗原之间的结构多样性及其在血清分型中的意义。
Front Microbiol. 2023 Jun 21;14:1191542. doi: 10.3389/fmicb.2023.1191542. eCollection 2023.
7
Healthcare-Associated Bloodstream Infections Due to Multidrug-Resistant in COVID-19 Intensive Care Unit: A Single-Center Retrospective Study.新型冠状病毒肺炎重症监护病房中耐多药菌所致的医疗相关血流感染：一项单中心回顾性研究
Microorganisms. 2023 Mar 17;11(3):774. doi: 10.3390/microorganisms11030774.
8
Distribution of Carbapenemase Genes among Carbapenem-Non-Susceptible Blood Isolates in Indonesia: A Multicenter Study.印度尼西亚碳青霉烯类不敏感血液分离株中碳青霉烯酶基因的分布：一项多中心研究
Antibiotics (Basel). 2022 Mar 9;11(3):366. doi: 10.3390/antibiotics11030366.
9
Antimicrobial and anti-biofilm potencies of dermcidin-derived peptide DCD-1L against Acinetobacter baumannii: an in vivo wound healing model.表皮抗菌肽 DCD-1L 对鲍曼不动杆菌的抗菌和抗生物膜效力：一种体内伤口愈合模型。
BMC Microbiol. 2022 Jan 13;22(1):25. doi: 10.1186/s12866-022-02439-8.
10
An Outbreak of (X6)-Carrying Tigecycline-Resistant Isolates with a New Capsular Type at a Hospital in Taiwan.台湾一家医院出现携带新型荚膜型（X6）的耐替加环素分离株疫情。
Antibiotics (Basel). 2021 Oct 12;10(10):1239. doi: 10.3390/antibiotics10101239.
Aspergillomarasmine A overcomes metallo-β-lactamase antibiotic resistance.
aspergillomarasmine A 克服金属β-内酰胺酶抗生素耐药性。
Nature. 2014 Jun 26;510(7506):503-6. doi: 10.1038/nature13445.
4
Combination therapy for carbapenem-resistant Gram-negative bacteria.碳青霉烯类耐药革兰氏阴性菌的联合治疗。
J Antimicrob Chemother. 2014 Sep;69(9):2305-9. doi: 10.1093/jac/dku168. Epub 2014 May 28.
5
Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012).头孢洛扎/他唑巴坦对来自美国和欧洲医疗机构住院肺炎患者分离的革兰氏阴性细菌的活性研究（2012 年）。
Int J Antimicrob Agents. 2014 Jun;43(6):533-9. doi: 10.1016/j.ijantimicag.2014.01.032. Epub 2014 Mar 26.
6
Clinical outcomes of hospital-acquired infection with Acinetobacter nosocomialis and Acinetobacter pittii.医院获得性嗜麦芽窄食单胞菌和皮氏不动杆菌感染的临床结局
Antimicrob Agents Chemother. 2014 Jul;58(7):4172-9. doi: 10.1128/AAC.02992-14. Epub 2014 May 12.
7
Identification, genotypic relation, and clinical features of colistin-resistant isolates of Acinetobacter genomic species 13BJ/14TU from bloodstreams of patients in a university hospital.某大学医院患者血流中鲍曼不动杆菌基因组种13BJ/14TU耐黏菌素分离株的鉴定、基因型关系及临床特征
J Clin Microbiol. 2014 Mar;52(3):931-9. doi: 10.1128/JCM.02868-13. Epub 2014 Jan 8.
8
Molecular mechanisms involved in the response to desiccation stress and persistence in Acinetobacter baumannii.鲍曼不动杆菌中参与对干燥应激反应及存活的分子机制。
J Proteome Res. 2014 Feb 7;13(2):460-76. doi: 10.1021/pr400603f. Epub 2013 Dec 17.
9
Spread of carbapenem-resistant Acinetobacter baumannii global clone 2 in Asia and AbaR-type resistance islands.碳青霉烯类耐药鲍曼不动杆菌全球克隆 2 在亚洲的传播和 AbaR 型耐药岛。
Antimicrob Agents Chemother. 2013 Nov;57(11):5239-46. doi: 10.1128/AAC.00633-13. Epub 2013 Aug 12.
10
Efficacy of tigecycline for the treatment of complicated intra-abdominal infections in real-life clinical practice from five European observational studies.五项欧洲观察性研究表明替加环素治疗真实临床实践中复杂性腹腔内感染的疗效。
J Antimicrob Chemother. 2013 Jul;68 Suppl 2:ii25-35. doi: 10.1093/jac/dkt142.